Immunotherapy Research Institute

Immunotherapy Research Institute (IRI) is a biotechnology company focused on the development of next-generation immune cell therapies and vaccines for cancer and infectious diseases. The company leverages a proprietary platform for the activation and expansion of Natural Killer (NK) cells and T cells to enhance their anti-tumor efficacy. IRI's research pipeline includes autologous and allogeneic cell therapy candidates designed to target a variety of solid tumors and hematological cancers. By integrating advanced immunology with clinical research, the institute aims to provide more effective and less toxic treatment options for patients with limited therapeutic alternatives.